sever
acut
respiratori
syndrom
sar
led
lifethreaten
form
atyp
pneumonia
late
follow
middl
east
respiratori
syndrom
merscov
recent
emerg
kill
patient
infect
global
mainli
saudi
arabia
south
korea
base
scaffold
report
inhibit
neuraminidas
na
synthes
analogu
identifi
compound
low
micromolar
inhibitori
activ
pro
sarscov
merscov
dock
studi
show
carboxyl
present
either
r
r
destabil
oxyanion
hole
pro
interestingli
could
inhibit
na
pro
serv
start
point
develop
broadspectrum
antivir
agent
sever
acut
respiratori
syndrom
sar
led
lifethreaten
form
atyp
pneumonia
late
march
caus
agent
identifi
name
sar
coronaviru
sarscov
sarscov
belong
genu
coronavirida
envelop
positivestrand
viru
nucleotid
viral
genom
encod
two
polyprotein
kda
kda
proteas
pro
main
proteas
papainlik
proteas
pl
pro
cleav
polyprotein
gener
nonstructur
protein
essenti
viral
replic
due
vital
role
replic
pro
attract
drug
target
mani
inhibitor
discov
high
throughput
screen
structurebas
ration
design
although
sarscov
infect
die
soon
anoth
human
cov
associ
middl
east
respiratori
syndrom
merscov
recent
emerg
kill
patient
infect
global
mainli
saudi
arabia
south
korea
due
similar
matur
pathway
merscov
pro
also
regard
target
develop
antivir
drug
previous
report
sarscov
pro
inhibitor
potent
inhibit
merscov
pro
without
modif
due
subtl
structur
differ
activ
site
though
tremend
effort
made
develop
inhibitor
therapeut
intervent
continu
outbreak
deadli
cov
yet
reach
market
origin
sar
date
back
earli
influenza
centuryold
histori
affect
human
influenza
viru
envelop
rna
viru
belong
orthomyxovirida
famili
caus
four
major
pandem
last
centuri
name
spanish
flu
asian
flu
hong
kong
flu
russian
flu
spanish
flu
pandem
claim
million
live
worldwid
recent
outbreak
china
along
viru
mutat
seriou
concern
one
access
target
neuraminidas
na
essenti
releas
viral
particl
cell
surfac
target
market
drug
oseltamivir
zanamivir
recent
report
new
inhibitor
type
na
also
show
antivir
activ
cellbas
assay
due
structur
similar
previous
discov
sarscov
pro
inhibitor
screen
na
inhibitor
sarscov
merscov
pro
synthes
analogu
hit
establish
structureactivityrelationship
sar
pro
report
herein
tabl
compound
synthes
describ
scheme
pyrazolon
core
synthes
condens
substitut
hydrazin
variou
bketoest
substitut
aldehyd
synthes
meerwein
aryl
substitut
diazonium
salt
furfur
catalyt
amount
sodium
acet
acet
acid
yield
final
compound
chromatograph
purif
requir
compound
pure
compound
could
obtain
methanol
wash
absenc
noe
signal
olefin
r
phenyl
proton
nmr
confirm
pyrazolon
singl
eisom
howev
methyl
substitut
r
gave
geometr
isom
ez
insepar
due
rapid
interconvers
solut
assay
result
confirm
bulkier
phenyl
group
r
essenti
inhibitori
activ
compound
ch
cf
posit
unabl
inhibit
sar
pro
carboxyl
moieti
seem
essenti
compon
compound
without
r
r
inact
remov
r
carboxyl
ic
lm
retain
r
result
ic
lm
improv
activ
ic
lm
carboxyl
r
potent
compar
respect
result
conclud
carboxyl
moieti
import
pharmacophor
presenc
either
r
r
critic
activ
equipot
chlorin
r
slightli
chang
activ
observ
decreas
activ
compar
respect
substitu
ring
also
import
compound
electronwithdraw
f
cn
show
signific
differ
activ
electrondon
methoxi
group
ring
caus
drop
activ
compar
without
substitu
studi
effect
ring
b
furan
ring
replac
aromat
system
obtain
scheme
signific
chang
activ
ic
lm
compar
ic
lm
ring
critic
absenc
ring
abolish
activ
replac
rigid
link
ring
b
ether
linkag
studi
effect
interestingli
flexibl
ether
linkag
ic
lm
scheme
alter
activ
compar
ic
lm
sar
studi
reach
conclus
pharmacophor
phenyl
r
carboxyl
either
r
r
essenti
activ
modif
ring
b
toler
well
alter
enhanc
activ
compound
observ
inhibitori
activ
sar
pro
ration
dock
simul
use
ligand
bound
crystal
structur
pdb
id
dock
simul
option
accur
dock
igemdock
use
gener
solut
ration
inhibitori
effect
molecul
must
first
understand
amino
acid
constitut
activ
site
pro
activ
site
pro
divid
subsit
subsit
made
vital
catalyt
residu
form
catalyt
dyad
process
polyprotein
eleven
site
compris
conserv
gln
follow
small
amino
acid
like
ser
ala
gli
vital
compon
subsit
oxyanion
hole
form
interact
ctermin
carboxyl
anion
conserv
gln
stabil
transit
state
proteolysi
entranc
pocket
interact
via
hbond
conserv
gln
subsit
contain
hydrophob
bulki
side
chain
like
val
leu
phe
subsit
near
surfac
activ
site
littl
role
substrat
bind
dock
fig
show
compound
lm
ic
bind
sar
pro
subsit
obstruct
substrat
bind
subsit
r
carboxyl
repres
form
hbond
vital
residu
form
oxyanion
hole
prevent
effici
cleavag
substrat
obstruct
stabil
tetrahedr
intermedi
form
transit
state
carboxyl
moieti
compound
make
addit
hbond
subsit
respons
specif
proteas
toward
conserv
gln
residu
furan
ring
interact
hydrophob
side
chain
subsit
shown
due
hydrophob
natur
subsit
addit
alkyl
substitut
ring
enhanc
interact
hydrophob
contact
addit
contact
seem
respons
enhanc
inhibit
compar
addit
hydrophob
interact
carbonyl
moieti
pyrazolon
core
interact
hbond
destabil
catalyt
dyad
remov
r
chlorin
compar
respect
unfavor
reorient
molecul
lose
hbond
fig
explain
observ
drop
activ
remov
chlorin
unlik
compound
seri
seem
occupi
subsit
fig
carboxyl
moieti
r
posit
interact
r
phenyl
group
prefer
hydrophob
pocket
ring
b
hydrophob
sit
well
subsit
ring
seem
form
weak
pp
stack
thu
destabil
catalyt
dyad
nitrogen
atom
pyrazolon
core
seem
interact
locat
entranc
pocket
prevent
bind
gln
substrat
modif
signific
effect
prefer
bind
similar
conform
shown
sinc
pro
merscov
sarscov
structur
similar
express
merscov
pro
test
compound
sarscov
pro
inhibitor
found
inhibit
merscov
pro
effect
low
micromolar
concentr
compound
bulkier
group
electronwithdrawingdon
hydrophob
substitu
ring
ic
around
lm
similar
sar
pro
presenc
carboxyl
moieti
seem
essenti
inhibit
mer
pro
compound
carboxyl
moieti
ring
best
inhibitor
ic
lm
compound
carboxyl
ring
unsubstitut
substitut
ring
less
bulkier
group
like
fluorin
remov
chlorin
atom
caus
signific
loss
activ
compar
lm
lm
fluorosubstitut
lm
lm
howev
presenc
bulkier
substitu
lm
lm
lost
activ
regain
remov
chlorin
compound
bulkier
ring
insignific
effect
inhibit
lm
lm
show
activ
similar
lm
lm
respect
recent
solv
crystal
structur
pdb
id
merscov
pro
gave
insight
structur
differ
two
pro
replac
residu
sar
pro
case
mer
pro
shrunk
subsit
prevent
latter
accommod
bulkier
group
unlik
sarscov
pro
accommod
ring
b
smaller
subsit
merscov
pro
accommod
phenyl
moieti
r
fig
smaller
size
make
molecul
r
phenyl
group
fit
snugli
activ
site
merscov
pro
reason
behind
activ
compound
equipot
subsit
r
interact
via
pp
stack
interact
perturb
catalyt
dyad
subsit
best
inhibitor
fig
carboxyl
moieti
ring
interact
destabil
oxyanion
hole
carbonyl
moieti
pyrazolon
core
also
interact
entranc
subsit
subsit
r
phenyl
form
pp
stack
perturb
catalyt
dyad
ring
b
primarili
hydrophob
interact
side
chain
subsit
compound
unsubstitut
phenyl
group
r
prefer
hydrophob
ring
c
form
tshape
pp
stack
destabil
oxyanion
hole
fig
remov
chlorin
atom
caus
loss
activ
compar
due
loss
tshape
pp
stack
fig
addit
ring
interact
hydrophob
side
chain
howev
ring
substitut
bulkier
group
remov
chlorin
make
signific
chang
activ
molecul
maintain
similar
interact
subsit
shown
comparison
inhibit
sar
pro
activ
compound
potent
mer
pro
case
differ
ic
reach
smaller
size
mer
pro
accommod
r
phenyl
group
therefor
substitut
ring
forc
occupi
make
better
interact
andor
subsit
point
illustr
figur
electron
densiti
reflect
shape
size
activ
site
transpar
carbon
skeleton
inhibitor
present
interest
compound
could
inhibit
neuraminidas
na
ic
lm
respect
two
pro
lowmicromolar
concentr
although
na
pro
homolog
protein
observ
share
similar
arrang
electronrich
amino
acid
residu
activ
site
na
contain
arginin
triad
pro
contain
cysteinehistidin
dyad
activ
site
essenti
substrat
process
activ
site
occupi
mainli
two
pharmacophor
name
carboxyl
phenyl
ring
carboxyl
present
r
interact
vital
arginin
residu
case
na
destabil
oxyanion
hole
mer
pro
fig
anoth
pharmacophor
r
phenyl
interact
pp
stack
insid
activ
site
na
pro
respect
base
common
scaffold
optim
na
inhibitor
inhibitor
pro
sarscov
merscov
thu
discov
broadspectrum
inhibitor
effect
drug
target
coronavirus
avian
influenza
viru
best
knowledg
report
regard
common
inhibitor
target
coronaviru
influenza
viru
literatur
still
drug
recent
emerg
merscov
infect
report
rais
possibl
modifi
known
inhibitor
na
inhibit
pro
vice
versa
approach
tri
mer
use
clinic
approv
drug
escal
cost
drug
discoveri
concept
drug
repurpos
gain
import
develop
antivir
agent
broadspectrum
activ
might
advantag
overcom
financi
hurdl
drug
discoveri
shall
look
modif
molecul
keep
pharmacophor
intact
seem
vital
broadspectrum
activ
compound
pyrazol
ring
surround
three
hydrophob
group
also
report
inhibit
proteas
human
picornavirus
rhinoviru
enteroviru
coxsackieviru
addit
pro
coronavirus
effort
made
cocrystal
compound
enzym
cellbas
assay
would
need
facilit
develop
potent
inhibitor
could
clinic
use
commerci
reagent
sigmaaldrich
acro
alfaaesar
use
provid
solvent
highest
puriti
proton
nuclear
magnet
reson
h
nmr
spectra
record
mhz
mhz
spectromet
carbon
nuclear
magnet
reson
c
nmr
spectra
record
mhz
mhz
spectromet
chemic
shift
report
part
per
million
ppm
rel
solvent
signal
describ
br
broad
singlet
doublet
dd
doublet
doublet
dddd
doublet
doublet
doublet
doublet
triplet
multiplet
coupl
constant
j
valu
given
hz
high
resolut
mass
spectrometri
hrm
obtain
bruker
biotof
ii
mass
spectromet
esitofm
spectra
record
reaction
monitor
silica
gel
f
thin
layer
plate
tlc
merck
benzoic
acid
equiv
diazot
nano
hcl
mixtur
gradual
ad
furfur
equiv
aceton
maintain
temperatur
around
follow
addit
copper
ii
chlorid
equiv
water
reaction
mixtur
maintain
h
allow
gradual
attain
room
temperatur
reaction
continu
room
temperatur
h
precipit
obtain
filter
wash
methanolwat
mixtur
obtain
pale
yellow
compound
equiv
bketoest
ml
acet
acid
ad
equiv
substitut
phenylhydrazin
hcl
salt
equiv
triethylamin
ad
content
reflux
h
content
cool
solvent
remov
vacuo
precipit
flask
ad
ethylacet
suspend
product
filter
obtain
pure
compound
thu
obtain
product
dri
yield
substitut
pyrazolon
note
case
product
isol
tautom
due
ketoenol
tautomer
equimolar
amount
taken
acet
acid
ad
catalyt
amount
sodium
acet
equiv
content
reflux
product
start
precipit
reaction
continu
h
solvent
remov
vacuo
follow
addit
methanolwat
mixtur
filter
crude
compound
thoroughli
wash
methanolwat
mixtur
remov
impur
trace
start
materi
get
final
compound
compound
purifi
use
flash
column
use
ethylacet
hexan
acet
acid
solvent
system
express
purif
sarscov
follow
report
procedur
express
merscov
pro
factor
xa
cleavag
site
iegr
pro
access
dna
sequenc
synthes
clone
express
vector
mission
biotech
compani
taiwan
transform
escherichia
coli
ml
overnight
cultur
singl
transform
use
inocul
fresh
lb
medium
contain
lgml
ampicillin
cell
grown
induc
mm
isopropylbthiogalactopyranosid
iptg
h
cell
harvest
centrifug
min
pellet
suspend
lysi
buffer
mm
trishcl
mm
nacl
mm
edta
mm
dtt
ph
frenchpress
instrument
constant
cell
disrupt
system
use
disrupt
cell
psi
centrifug
h
discard
debri
cellfre
extract
load
onto
ninta
column
equilibr
lysi
buffer
contain
mm
imidazol
exhaust
wash
lysi
buffer
imidazol
concentr
wash
buffer
increas
mm
protein
elut
lysi
buffer
mm
imidazol
dialyz
lysi
buffer
remov
imidazol
factor
xa
ad
fusion
protein
final
concentr
ww
incub
h
remov
histag
subsequ
process
merscov
pro
pass
ninta
column
purif
protein
concentr
determin
protein
assay
kit
biorad
usa
bsa
use
standard
fluorometr
assay
util
determin
inhibit
constant
prepar
sampl
fluorogen
peptid
dabcylktsavlqsgfrkmeedan
use
substrat
enhanc
fluoresc
due
cleavag
substrat
catalyz
pro
monitor
nm
excit
nm
ic
valu
individu
sampl
measur
reaction
mixtur
contain
nm
sar
pro
nm
merscov
pro
lm
fluorogen
substrat
mm
bistri
ph
